drugset / Trial / NCT02392702

Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

NCT02392702

Phase 1 Completed 15 enrolled Concert Pharmaceuticals
RandomizedCrossoverOpen-labelBasic science

Summary

This two-part study will assess, in healthy volunteers, under both fasted and fed conditions, and in a sequential manner, the safety, tolerability and pharmacokinetics (PK) profile of single doses of C-10355 and C-10358 and single ascending doses of the selected compound compared to a single dose of Kalydeco®.

Timeline

Start
2015-03
Primary completion
2015-06
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator C-10355 Unknown 25 mg Oral
Comparator C-10355 Unknown 75 mg Oral
Comparator C-10355 Unknown 150 mg Oral
Comparator C-10355 Unknown 300 mg Oral
Comparator C-10358 Unknown 25 mg Oral
Comparator C-10358 Unknown 75 mg Oral
Comparator C-10358 Unknown 150 mg Oral
Comparator C-10358 Unknown 300 mg Oral
Comparator Ivacaftor Other / unclassified 150 mg Oral

Indications

No indication recorded.